Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q2 FY23 Earnings Presentation
16 slides from Aurobindo Pharma's earnings presentation, Nov 12, 2022
Slide 1: Exchange cover letter: Investor / Analysts Presentation
November 12, 2022 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Compan
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q2FY23
Aurobindo Pharma Limited Earnings Presentation Q2FY23
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Index
Index Page Q2FY23 Business & Financial Highlights 4 Financial Performance 9 Filings Snapshot 12 Aurobindo Pharma Limited | Earnings Presentation – Q2FY23 3
Slide 5: Q2FY23 Business & Financial Highlights
Q2FY23 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q2 FY23
Quarterly Performance – Q2 FY23 Revenue (Rs Crore) US Revenue ($ Mn) 6,236 5,942 6,002 5,809 5,702 5,739 401 364 367 363 386 331 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 EBITDA (Rs Crore) Net Debt to Equity* 1,209 1,187 0.00 1,016 -0.01 974 965 837 -0.07 -0
Slide 7: Consolidated Financial & Business Highlights – Q2 FY23
Consolidated Financial & Business Highlights – Q2 FY23 Revenue from operations at Rs 5,739.4 crore, US revenues at US$ 331 Million Research & Development (R&D) spend at Rs 276 crore in Q2FY23, 4.8% of revenue Vs. Rs. 310 crore in Q1FY23, 5.0% of revenue EBIDTA before Forex and Other income at Rs 836
Slide 8: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Crore) Revenue mix – Q2FY23 2,968 2,971 Orals 2,638 69.5% Total Injectables Injectables* 14.8% 22.5% Branded Oncology** Q2FY22 Q1FY23 Q2FY23 7.7% OTC 7.9% US Formulations • US revenue in Q2FY23 decreased by 11% YoY and QoQ to Rs. 2,638 crore, accounting
Slide 9: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights In Rs Cr Europe Growth Markets ARV API 452 1,662 969 907 431 380 1,548 1,516 781 386 164 145 Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 Q2FY22 Q1FY23 Q2FY23 • Europe revenue in Q2FY23 was • Revenue from G
Slide 10: Financial Performance
} | AUROBIND Committed to healthier life! 203 Windsor Center Drive
Slide 11: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q2FY23 Q2FY22 (%) Chg Q1FY23 (%) Chg Revenue from operations 5,739.4 5,941.9 -3.4 6,235.9 -8.0 Gross Profit 3,171.3 3,436.3 -7.7 3,349.2 -5.3 Gross Margin 55.3% 57.8% 53.7% Overheads 2,334.4 2,249.6 3.8 2,384.5 -2.1 EBITDA (before forex and ot
Slide 12: Debt profile
Debt profile Debt as on (Rs Cr) Mar-20 Mar-21 Mar-22 Jun-22 Sep-22 Fx Loan US$ Mn Closing Rate1 US$ = INR 75.66 73.11 75.79 78.97 81.345 732 674 313 277 495 Fx Loan restated in INR 5,549.2 4.928.8 2,222.7 2,190.6 3,599.9 Rupee Loan 16.9 43.6 150.1 0.0 420.8 Gross Debt 5,566.1 4,972.4 2,372.8 2,190.6
Slide 13: Filing Status
} | AUROBIND Committed to healthier life! 203 Windsor Center Drive
Slide 14: US Filings Snapshot as on 30th Sep 2022
US Filings Snapshot as on 30th Sep 2022 ANDA Filings Aurobindo (Excl. Eugia Pharma Eugia Pharma Specialty Group Addressable 527 Therapy ANDAs Market Size 389 138 (US$ Bn) Specialty Group) CNS 138 27.75 193 70 159 CVS 108 37.04 36 ARV** 39 0.75 Final Tentative Under Gastroenterological 41 3.83 Approv
Slide 15: Global regulatory filing details
Global regulatory filing details As at As at As at As at As at As at As at As at As at Category Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Jun 22 Sep 22 Formulations US* 398 429 478 541 586 639 727 741 756 (FA: 527, TA:36) 3,005 Dossiers (360 Europe** 2,224 2,521 2,848 3,003 3,214 3,
Slide 16: Thank You
Thank You For more information, contact Investor Relations | Corporate Communications +91 40 6672 5041 ir@aurobindo.com www.aurobindo.com